Pet Dogs Bring Both Joy and Worry to Displaced Gaza Teenager 

Displaced Palestinian teenager Hassan Abu Saman holds his dog on a beach, amid the ongoing conflict between Israel and the Palestinian group Hamas, in Rafah, in the southern Gaza Strip, February 20, 2024. (Reuters)
Displaced Palestinian teenager Hassan Abu Saman holds his dog on a beach, amid the ongoing conflict between Israel and the Palestinian group Hamas, in Rafah, in the southern Gaza Strip, February 20, 2024. (Reuters)
TT

Pet Dogs Bring Both Joy and Worry to Displaced Gaza Teenager 

Displaced Palestinian teenager Hassan Abu Saman holds his dog on a beach, amid the ongoing conflict between Israel and the Palestinian group Hamas, in Rafah, in the southern Gaza Strip, February 20, 2024. (Reuters)
Displaced Palestinian teenager Hassan Abu Saman holds his dog on a beach, amid the ongoing conflict between Israel and the Palestinian group Hamas, in Rafah, in the southern Gaza Strip, February 20, 2024. (Reuters)

Keeping three dogs while living in a tent on a beach in Gaza complicates an already difficult situation, but the smile on teenager Hassan Abu Saman's face when he pets the animals shows that it's worth the trouble for him.

A passionate dog lover since childhood, he had 16 of them before the Israel-Hamas war that has devastated the Gaza Strip, but managed to take just three of them, Mofaz, Lucy and Dahab, when he fled his home in Al-Nuseirat refugee camp in central Gaza.

"When things settled, I was able to secure a car to go and get the rest, but when I got back, I did not find any of them, they were lost. I went back a second time to look for them and found the house bombed," said Abu Saman, 17.

He is one of the estimated 1.5 million Palestinians crammed into Rafah in southern Gaza, close to the boundary with Egypt, to escape from Israel's military onslaught -- although Israel has said it was planning a ground offensive there too.

Abu Saman is living in a sprawling tent camp in a beach area on the outskirts of Rafah, along with family members and the three dogs, who follow him everywhere he goes. They are popular with camp children who take turns stroking them.

Abu Saman referred to the dogs as "my friends from another kind" and spoke about them as he would about people.

"He has been feeling so down because of the war," he said of Mofaz, the largest of the three.

Finding enough food was a problem for dogs as well as humans, and Abu Saman said Lucy and Dahab had lost weight because they usually ate a special kind of dog food that was no longer available.

The future was uncertain for the teenager, his family and his beloved pets.

"If we were to return, the house is flattened. He does not have a house or anything," he said, referring to Mofaz, who he was stroking while talking.

The war was triggered by Hamas militants who attacked southern Israel on Oct. 7, killing 1,200 people and taking 253 hostage, according to Israel.

Vowing to destroy Hamas, Israel has responded with an air and ground assault on Gaza that has killed more than 29,000 people, according to local health officials. It has also displaced most of the population of 2.3 million, caused widespread hunger and reduced much of the territory to rubble.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”